Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice

Bo Ahren*
Department of Clinical Sciences Lund, Lund university, Lund, Sweden

Keywords
Fat, Glucose, Glucose-dependent insulinotropic polypeptide, Humans, Macronutrients, Mice, Protein

*Correspondence
Bo Ahren
Tel: +46705520758
E-mail address: bo.ahren@med.lu.se

J Diabetes Investig 2022; 13: 1655–1665
doi: 10.1111/jdi.13836

ABSTRACT

Aims/Introduction: The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is secreted after meal ingestion. This study explored the relative influence of classes of macronutrients on GIP secretion.

Materials and Methods: The human literature was revisited by identifying articles from PubMed using key words GIP, macronutrients, carbohydrates, fat, protein, healthy subjects. In model experiments in anesthetized mice, glucose (25–125 mg), protein (15–120 mg), fat emulsion (6–100 mg) or saline was given orally with determination of GIP levels.

Results: The literature survey identified 15 studies in which glucose, protein or fat was administered to healthy subjects. All three classes of macronutrients stimulated GIP secretion with a 30–45 min peak after glucose and protein, and a more prolonged release after fat. Limitations in study designs preclude firm conclusions on the relative potency of the macronutrients. In mice, glucose was more potent to stimulate GIP secretion than fat and protein, with no significant difference between protein and fat. By co-administration of the macronutrients at moderate caloric combinations, a synergistic stimulation of GIP secretion was observed. In contrast, when raising the glucose challenge together with protein and fat, no synergy, but an additive effect, was evident.

Conclusions: Glucose, protein and fat all stimulate GIP secretion in humans and mice. In mice, glucose is more potent than fat and protein, and there is also a synergy between the macronutrients on GIP secretion at moderate caloric doses. Further studies are warranted in humans to explore the relative potency of macronutrients.

INTRODUCTION

Glucose-dependent insulinoergic peptide (GIP) was isolated from the gut in 1969 and shown to inhibit gastric acid secretion. It was subsequently shown that the main effect of the hormone is its glucose-dependent stimulation of insulin secretion. Further studies have shown that GIP is produced in the K cells, which are mainly located in the upper portion of the gut; that GIP is released after meal ingestion and oral glucose in humans, and enhances insulin secretion at physiological levels; and that a GIP antagonist reduces insulin secretion after oral glucose in humans. These data collectively suggest that GIP is an important incretin hormone, that is, a hormone that is released after oral glucose or meal ingestion and that stimulates insulin secretion.

A characteristic of an incretin hormone is that it is released after meal ingestion. For GIP, we have shown that GIP levels are markedly increased during the first 30 min after meal ingestion in healthy individuals, whereafter they remain persistently elevated for 3 h. We have, furthermore, also shown that GIP secretion is dependent on the size of the meal. We have...
also shown that GIP secretion does not seem to be dependent on the time during the day when the meal is ingested), and is independent on the rapidity of meal ingestion.

Studies on individual classes of macronutrients have shown that carbohydrates, fat and protein all stimulate GIP secretion. Conclusions on the relative potencies of the individual classes of macronutrients for GIP secretion are, however, limited, because there are only a few studies that have examined more than one class of macronutrients, and in most studies only one dose of each macronutrient was tested. In addition, although one study suggested a synergy between different macronutrients when they were given together, this has not been studied systematically. To more systematically explore the relative potency of different classes of macronutrients for GIP secretion and their potential synergy, we have in the present study, first, revisited the human literature to explore studies in which individual classes of macronutrients have been ingested and, second, carried out model experiments in mice.

**MATERIALS AND METHODS**

**Human studies revisited**

Studies in which GIP levels were determined after ingestion of carbohydrates, fat or protein in healthy individuals were included in the literature survey. They were identified from review articles on GIP, macronutrients, carbohydrates, fat, protein and healthy subjects. Key aspects of each article were identified and reported in the result section and in Table 1.

**Animal studies**

Experiments were undertaken in female C57BL/6J mice (Tacobeck, Skensved, Denmark; 4–6 months-of-age). Animals were maintained in a temperature-controlled room (22°C) on a 12:12 h light–dark cycle (light on at 07.00 hours). Mice were fed a standard pellet diet (energy 14.1 MJ/kg with 14% from fat, 60% from carbohydrate and 26% from protein; SAFE, Augy, France) and tap water ad libitum. During experimental days, food was removed from the cages at 07.30 hours or at 10.30 hours, and the experiments started at 09.30 hours or at 12.30 hours; that is, during the light cycle. We used female mice only to avoid the stress of single housing, which is used for male mice. We used the mice randomly during the estrous cycle.

**Experimental design**

Mice were fasted for 2 h. After the 2-h fast, mice were anesthetized with the combination of Fluafent (i.e., a mixture of fentanyl and midazolam) and studies in mice.

| Challenge                     | No. participants | Fold increase of GIP levels | Peak time (min) | Reference |
|-------------------------------|------------------|----------------------------|-----------------|-----------|
| Glucose 25 g                  | 12               | 9.2                        | 30              | 22        |
| Glucose 50 g                  | 10               | 3.2                        | 30              | 17        |
| Glucose 75 g                  | 10               | 3.7                        | 30              | 23        |
| Glucose 83 g                  | 18               | 2.3                        | 30              | 24        |
| Glucose 100 g                 | 45               | 3.1                        | 30              | 25        |
| Glucose 163 g                 | 18               | 7.1                        | 30              | 28        |
| Glucose 22 g/kg               | 12               | 18.4                       | 30              | 19        |
| Protein                       |                  | No effect                  | No peak         | 8         |
| Grilled turkey (375 kcal)     | 8                | 7.1                        | 30              | 22        |
| Whey protein 18 g             | 12               | 6.5                        | 30              | 19        |
| Milk/egg protein (Promax2) 2 g/kg | 12          | 9.5                        | 30              | 18        |
| Beef extract (Bovril®) 45 g   | 6                | No effect                  | No peak         | 26        |
| Fat                           |                  |                            |                 |           |
| Corn oil 67 g                 | 10               | 4.9                        | 60              | 30        |
| Corn oil 70 g                 | 10               | 2                          | 120             | 17        |
| Oleic acid 0.88 g/kg          | 6                | 5.1                        | 180             | 26        |
| Long-chain triglycerides (110 kcal) | 12        | 2.9                        | 120             | 18        |
| Double cream 84 mL (375 kcal) | 12               | 8.2                        | 120             | 19        |
| Soybean oil (Intralipid®) 0.9 g/kg | 12        | 3.5                        | 90              | 8         |
| Double cream 200 mL 96 g      | 5                | 8.5                        | 120             | 31        |
described. In short, 10 mg fluanisone (Key Organics, Cambridge, UK) was dissolved in 1 mL sterile water at 70°C for 60 min. This solution was mixed with 1 mL of fentanyl citrate (0.315 mg/mL; Sigma-Aldrich, St. Louis, MO, USA); 100 µL of this solution were given intraperitoneally to each mouse (0.016 mg fentanyl citrate and 0.5 mg fluanisone/mouse). Midazolam (0.167 mg/mouse; Roche, Basel, Switzerland) was also given (100 µL/mouse). Mice were then given glucose (25–125 mg per mouse, dissolved in saline; Sigma-Aldrich), protein mixture (whey protein, 15–120 mg/mouse; dissolved in saline; SELF Omninutrition, Skogås, Sweden) or fat emulsion (CalygênR Neutral, which is based on vegetable fat (from rapeseed and sunflower oil) with 50% long-chain triglycerides (10.6% saturated, 61% monounsaturated and 28.6% polyunsaturated) and 50% water (6–100 mg per mouse; Nutricia Nordica AB, Solna, Sweden) or saline alone or macronutrients mixed together in the stomach through a gastric tube (diameter 1.2 mm). Whole blood was sampled in heparinized pipettes from the intraorbital retrobulbar sinus plexus (40 µL) at 0, 15, 30 and 60 min. Plasma was separated by centrifugation and stored at −20°C until analysis for GIP and insulin.

Analyses
Glucose in whole blood was detected with the glucose oxidase method using AccuChek Aviva (Hoffman-La Roche, Basel, Switzerland). Insulin was determined by enzyme-linked immunosorbent assay (Mercodia, Uppsala, Sweden). The intra-assay coefficient of variation of the method was 4% at both low and high levels, and the interassay coefficient of variation was 5% at both low and high levels. The lower limit of quantification of the assay was 6 pmol/L. Total GIP levels were determined with a mouse GIP enzyme-linked immunosorbent assay kit (Crystal Chem, Elk Grove Village, IL, USA). The intra- and interassay coefficient of variation was <10% at low and high levels, and the lower limit of quantification was 2.5 pmol/L. The assay showed no cross-reactivity with glucagon, glucagon-like peptide (GLP)-1 or GLP-2.

Statistical analysis
Data are presented as the mean ± standard error of the mean. Suprabasal (incremental) areas under the curves (AUCs) were calculated with the trapezoid rule using GIP levels throughout the 60-min study period. Differences between experimental groups were determined using a two-way analysis of variance (ANOVA) followed by a Sidak’s multiple comparisons test using SPSS (version 27; IBM Corp., Armonk, NY, USA). Statistical significance was defined as P < 0.05.

RESULTS
Human literature survey
Glucose ingestion
In 11 human studies, glucose was administered orally. All these studies reported an increase in GIP levels after oral glucose with the peak seen at 30 or 45 min. In most studies, peak levels were 2–4-fold higher than baseline levels, although a few studies reported a higher fold increase. There was no association between glucose dose and fold increase when comparing the different studies (Table 1).

Protein ingestion
Five studies reported GIP levels after ingestion of a protein load. Three of them reported an increase in GIP levels with a 6–9-fold increase of the peak levels at 30 min over baseline. In contrast, in two of the studies, no increase in GIP levels were observed.8,26

Fat ingestion
In eight studies, humans were challenged with various types of fat, and GIP levels increased in all of them.8,17–19,22,29–31 Peak levels were in most studies reported at 2 h after fat ingestion. Fold increase in peak GIP levels over baseline levels varied between two and 8.5, with no association with amount of fat ingested.

Model experiments in mice
Administration of macronutrients alone
Glucose, whey protein and fat emulsion all increased GIP levels (Figures 1 and 2; Table 2). Glucose was most efficient and increased GIP levels to >300 pmol/L after the highest dose of 125 mg. Peak GIP levels after glucose were seen at 15–30 min, whereafter GIP levels gradually returned to baseline. The threshold dose of glucose to increase GIP levels was between 25 and 50 mg, as after 25 mg glucose, there was no significant increase in GIP levels compared with controls at any time point, whereas after 50 mg glucose, there was a significant increase in GIP levels at 15 min (P = 0.003) and 30 min (P = 0.030). After 100 mg and 125 mg glucose, GIP levels increased at all time points compared with controls (P < 0.001 at all time points). Insulin levels increased by glucose after 100 and 125 mg glucose, with significantly increased GIP levels after 100 mg glucose at 15 min (P = 0.004) and 30 min (P < 0.001), and after 125 mg glucose also at 60 min (P = 0.018). Glucose levels were significantly higher after all four doses of glucose than in controls at 15, 30 and 60 min (P < 0.001), except at 60 min after the low dose of 25 mg glucose. AUCGIP was significantly higher after 50 mg (P = 0.011), 100 mg (P < 0.001) and 125 mg glucose (P < 0.001) than in controls, but not after 25 mg. AUCharma was significantly increased after 100 mg and 125 mg glucose (both P < 0.001), and also close to significantly increased after 50 mg glucose (P = 0.058). AUCharm was significantly increased after all four doses of glucose (all P < 0.001). Protein administration increased GIP levels after 60 mg and 100 mg, but not after 15 mg. After 60 mg protein, GIP levels were significantly higher than in controls at 15 min (P < 0.001) and 30 min (P = 0.012), with a trend to be increased also at 60 min.
(\(P = 0.089\)). After 120 mg protein, GIP levels were significantly higher than in controls at 15, 30 and 60 min (all \(P < 0.001\)). Insulin levels were not increased after 15 mg protein. In contrast, insulin levels were higher than in controls after 60 mg protein at 15 min (\(P = 0.030\)) and after 120 mg protein at 30 min (\(P = 0.035\)). Glucose levels were not significantly affected by protein at any dose. AUCGIP was higher than in controls after 120 mg protein (both \(P < 0.001\)), whereas there was no significant difference between controls and fat after 6 or 24 mg in AUCGIP or AUCinsulin. AUCglucose did not differ from controls after any of the fat doses.

Figure 2 shows the dose–response relationships between doses of glucose, protein and fat, and AUCGIP, AUCinsulin and AUCglucose. When statistically analyzing effects of the highest doses, glucose was more potent in increasing AUCGIP than protein and fat (both \(P < 0.001\)), whereas there was no significant difference between protein and fat administration in regard to AUCinsulin and AUCglucose.

Co-administration of glucose, protein and fat
To study the potential synergistic effect on GIP levels after co-administering glucose, protein and fat, we used the model of meal tolerance test (MTT; 32). Five different combinations were
used. First, we administered a mixed meal with 314 calories (50 mg glucose, 15 mg protein and 6 mg fat) (Figure 3; Table 3), which was selected to be in the same range as carried out in the previous study on GLP-1 secretion. It was found that after this challenge, GIP levels were enhanced similarly as after glucose alone; that is, the addition of protein and fat did not affect the response to glucose alone. Protein and fat addition, however, reduced the glucose and insulin responses compared with glucose alone. To further study the effects of the combination of the nutrients, we increased the dose of protein to 60 mg and fat to 24 mg, and examined how glucose addition from zero to 100 mg would affect the responses. It was found that at 456 and 556 calories (i.e., with glucose 0 or glucose 25 mg added to protein 60 mg and fat 24 mg), there was a synergistic action of the combinations on GIP levels, as these were enhanced significantly more than by adding up the response of each of the nutrients alone. Protein and fat addition, however, reduced the glucose and insulin responses compared with glucose alone. To further study the effects of the combination of the nutrients, we increased the dose of protein to 60 mg and fat to 24 mg, and examined how glucose addition from zero to 100 mg would affect the responses. It was found that at 456 and 556 calories (i.e., with glucose 0 or glucose 25 mg added to protein 60 mg and fat 24 mg), there was a synergistic action of the combinations on GIP levels, as these were enhanced significantly more than by adding up the response of each of the nutrients alone (Figure 3; Table 3). At the higher doses (656 and 856 calories, i.e., adding 50 or 100 mg glucose to protein 60 mg and fat 24 mg), the GIP responses were not significantly different from the sum of responses for each of the nutrients given alone; that is, an additive effect. Insulin responses were additive at 456, 556 and 656 calories, whereas a synergy was observed at 856 calories, showing that protein and fat addition enhanced the insulin response to glucose at these higher doses (Figure 4; Table 3). Furthermore, glucose levels were reduced after MTT at 556, 656 and 856 calories compared with the sum of the individual nutrients given alone; that is, adding the nutrients together reduced the expected increase in glucose levels. Table 3 shows the observed AUCGIP, AUCglucose and AUCinsulin after each of the MTT tests compared with the sum or responses of the individual macronutrients when given alone. Similarly, Figure 5 summarizes the GIP data for all five MTT challenges. A slight significant synergy was observed at the dose of 456 and 556 calories, whereas when glucose levels were raised to 50 and 100 mg, there was no additional synergy by protein and fat.

### DISCUSSION

Glucose-dependent insulinotropic polypeptide is an important incretin hormone in humans, which is evident by a study showing that infusion of a GIP receptor antagonist reduces insulin secretion after combined oral glucose and mixed meal challenge by 30%. Another experimental study in humans also showed that GIP is equally important as GLP-1 as an incretin hormone. To act as an incretin hormone, GIP is secreted into the circulation from the gut K cells after meal ingestion, with a peak level seen after approximately 30 min. The postprandial levels are, furthermore, sufficient to stimulate insulin secretion. Previous studies have presented characteristics of GIP secretion in humans. It has thus been shown that the size of the meal matters. Thus, ingestion of a meal with 743 kcal elicited a ≈25% higher GIP response than a 511 kcal meal with exactly the same macronutrient composition, and a 1,046 kcal meal.
enhanced the GIP response ≈20% further\textsuperscript{13}. In contrast, the time of the day does not seem to be of importance for GIP secretion, as the same meal elicited the same GIP response whether ingested at 08.00 hours versus at 17.00 hours\textsuperscript{11}. Similarly, rapid or slow ingestion of a meal does not seem to affect GIP secretion, as the same meal ingested over 5 versus over 12 min elicited the same GIP response\textsuperscript{14}.

The present study revisited the human literature on studies with ingestion of single classes of macronutrients with measurement of GIP levels. The survey clearly showed that there is a consensus between studies that glucose, protein and fat are classes of macronutrients that by themselves stimulate GIP secretion in humans (Table 1). One intention of carrying out this revisit was to explore whether it would be possible to conclude that one or the other of the macronutrients is more potent. Such a conclusion has previously been suggested based on early findings that protein ingestion seemed weaker to stimulate GIP secretion than glucose or fat\textsuperscript{3,8,10,26}. However, when

---

**Figure 3** | Glucose-dependent insulinotropic polypeptide (GIP), glucose and insulin levels before and after oral administration of a mixture of glucose, whey protein and fat emulsion or each of glucose, whey protein and fat emulsion alone in C57BL/6J mice. The caloric content of the mixed meal tolerance test (MTT) was 314 and 456 calories, respectively. Bottom of figure shows the composition of each text and number (n) of animals in each group. Observe that the y-axes for the respective panels have been adjusted for the actual levels and are therefore different for the different loads.
going through all relevant articles, it was obvious that it is not possible to draw such a conclusion. First, there are only very few studies in which more than one class of macronutrient is given⁸,¹⁸,²² and, second, in most studies, only one single dose of a given macronutrient is given. Third, for protein and fat, different types are given. All this makes it hard to compare the different studies. In fact, not even by analyzing a potential dose–response relationship of the effect of glucose on GIP secretion is possible. Therefore, the conclusion from the human literature is that glucose, protein and fat all have the capacity to stimulate GIP secretion.

Another consistent finding in the human literature is that the peak of GIP levels after macronutrient challenge differ between the macronutrients. Thus, after glucose and protein ingestion, GIP levels peak in most studies at 30 or 45 min; that is, within the same time frame as after a mixed meal. In contrast, fat administration is associated with a more prolonged and gradual increase in GIP levels, with a peak after approximately 2–3 h. Although the mechanism of this different time pattern needs to be established, the marked inhibition of gastric emptying, which is evident after fat ingestion, does probably contribute.

To study the relative potency of different classes of macronutrients more systematically, we turned to model experiments in mice, where we orally administered glucose, whey protein and a lipid emulsion with 50% long-chain triglycerides, and measured GIP levels. We administered glucose, protein and fat emulsion over a large dose range to enable conclusions of their relative potency. We found that glucose, protein and fat all increased GIP levels. Glucose administration increased GIP levels in a glucose-dependent manner with the threshold between 25 and 50 mg, and the strongest effect was seen by the highest dose of 125 mg. Also, protein administration increased GIP levels in a dose-dependent manner, with no increase after 15 mg, whereas after 60 mg, there was significantly increased GIP levels at 15 and 30 min. At the highest dose of 120 mg, GIP levels increased at all time points, also resulting in a significantly increased AUCGIP. Fat administration did not increase GIP levels at 6 mg, whereas at 24 mg there was a transient increase in GIP levels, and after 100 mg, there was a large and continuous increase in GIP levels. Peak GIP levels after glucose and protein were in general seen at 15 or 30 min, whereas after the high dose of fat emulsion, a prolonged and continuous increase in GIP levels was seen with no
observed peak within the 60-min study period. Hence, the different time patterns between glucose and fat, as were identified in human studies, were also evident in mice. An explanation is probably the inhibition of gastric emptying by fat \(,^{34,35}\), which results in different kinetics between glucose, protein and fat, as evident from plasma levels of glucose, amino acids and fat after administration. Thus, glucose levels are rapidly increased after administration, with a peak seen at 15 or 30 min (Figure 1). Also, amino acids are rapidly increased after protein administration, with peak levels at 30–60 min in humans \(,^{36}\), whereas fat levels are more slowly increased after fat administration, as we observed in a previous human study, where it took 180 min for triglyceride levels to be maximal after oral fat administration \(,^{29}\).

Our main finding of the present study was, however, that there indeed is a difference in the potency to stimulate GIP secretion between the classes of nutrients, as glucose was more potent than protein and fat. The earlier conclusion that protein would be less potent to stimulate GIP secretion than glucose \(,^{38,10,26}\) seems therefore to be valid, although, as in several human studies \(,^{18,19,22}\), there is a clear effect of protein ingestion to increase GIP levels. There was no significant difference in increasing GIP levels by the highest doses of protein versus fat, which would suggest that these nutrients stimulate GIP secretion by similar potency in mice. However, it should be emphasized that the continuous increase in GIP levels after 100 mg fat mg underestimates the true potency of fat administration by the design of the study with no data point after 60 min.

In our model experiments in mice, we also explored whether macronutrients when given together would have any synergistic action on GIP levels; that is, if their combined action on GIP levels would be significantly higher than expected from adding the responses of the individual macronutrients together or whether there is an additive response of the individual macronutrients. We previously carried out a similar study for GLP-1 secretion, and found that there is a clear synergism by the macronutrients to stimulate GLP-1 secretion in mice, as the GLP-1 response to macronutrients given together exceeded that of the sum of each individual macronutrient \(,^{32}\). We found that

---

**Figure 5** | Suprabasal area under the curve for glucose-dependent insulinotropic polypeptide (AUCGIP) after oral administration of a mixture of glucose, whey protein and fat emulsion in C57BL/6J mice compared with the sum of administration of individual macronutrients. The actually observed AUCGIP after each of the mixed meal tolerance test (MTT) challenges are reported in black, whereas the sum of AUCGIP after each of the individual macronutrients when given alone are shown in red. The y-axis shows caloric content of each mixture. The composition of each mixture is shown in at the bottom of the figure. Means ± standard error of the mean are shown. Asterisks indicate the probability level of random difference compared with the saline control; **P < 0.01, ***P < 0.001.

---

**Table 2** | Suprabasal (incremental) areas under the 0–60 min curves for glucose-dependent insulinotropic polypeptide, glucose and insulin levels after oral administration of glucose, whey protein or fat emulsion in normal C57BL/6J mice.

| Challenge    | n  | AUCGIP (nmol/L min) | AUCglucose (mmol/L min) | AUCinsulin (nmol/L min) |
|--------------|----|---------------------|-------------------------|------------------------|
| Saline       | 14 | 0.12 ± 0.09         | –21 ± 13                | –1.6 ± 1.7             |
| Glucose 25 mg| 12 | 1.0 ± 0.2           | 120 ± 14***             | 4.0 ± 1.5              |
| Glucose 50 mg| 15 | 4.2 ± 0.5*          | 281 ± 25***             | 17.9 ± 2.1             |
| Glucose 100 mg| 15 | 7.4 ± 0.9***        | 439 ± 21***             | 35.6 ± 15***           |
| Glucose 125 mg| 12 | 13.4 ± 1.8***       | 447 ± 35***             | 65.3 ± 9.2***          |
| Protein 15 mg| 11 | –0.2 ± 0.1          | –35 ± 11                | 0.5 ± 2.0              |
| Protein 60 mg| 12 | 0.5 ± 0.2           | –7 ± 8                  | 7.2 ± 2.1*             |
| Protein 120 mg| 12 | 1.0 ± 0.1***        | –47 ± 8                 | 6.4 ± 2.1*             |
| Fat 6 mg     | 13 | 0.2 ± 0.1           | –36 ± 10                | 14 ± 1.8               |
| Fat 24 mg    | 12 | 1.2 ± 0.2           | –7 ± 9                  | –1.8 ± 1.7             |
| Fat 100 mg   | 19 | 3.7 ± 0.6***        | 10 ± 9                  | 15.9 ± 4.0***          |

Means ± standard error of the mean are shown. Asterisks show the probability level of random difference compared with the saline control; **P < 0.05, ***P < 0.001. AUC, area under the curve.
there is also a trend for a synergy between the macronutrients for GIP secretion, as after 456 and 556 calorie ingestion of macronutrients together, the GIP response was significantly higher than by adding the response of each individual macronutrient together.

However, when increasing the caloric content by adding more glucose, it seems as if the effect of glucose dominates, such that there is no further augmentation by the protein and fat ingestion. This is most likely explained by the potent action of glucose alone, such that when GIP secretion is markedly stimulated by the high doses of glucose, the lower actions of protein and fat will not cause a synergistic enhancement, but only an additive. There is also a possibility that synergistic and saturated additive effects of different macronutrients are mediated by direct effects on the GIP secreting K cells, based on previous data on mechanistic aspects of stimulation of these cells\textsuperscript{37,38}. However, to what extent the synergistic action of the macronutrients at lower glucose levels is explained by direct effects on the GIP producing K cells and whether such effects are saturated at high-glucose doses remains to be studied.

In contrast, there is a clear effect on insulin levels (significantly enhanced) and glucose levels (being markedly reduced) by adding protein and fat to the glucose challenge. This shows that a mixed meal has a glucose-lowering effect compared with glucose alone, which also has been shown in humans\textsuperscript{19}. Our current data suggest, however, that this synergy of a mixed meal on glucose and insulin levels is not mediated by GIP.

A strength of our human literature survey was that we collected many studies with macronutrient ingestion, which allows a more general conclusion than is possible from each of the studies. Furthermore, a strength of the mouse study was that we used many different doses, both when giving macronutrients alone and together. A limitation of the present study was that we carried out the intervention part in mice only, which limits the potential conclusions for the human condition. Another potential limitation was that residual food content in the gut at the time of the experiments would have affected GIP secretion. However, it has been shown that gastrointestinal transit time in mice is such that 80% has passed through after 60 min\textsuperscript{39}, which suggests that this effect is probably minor in the present experiments in which the mice were fasted for 2 h.

In conclusion, we have identified several human studies where single classes of macronutrients have been given with determination of GIP levels, and we conclude that glucose, protein and fat all stimulate GIP secretion. Furthermore, there is no clear difference between the macronutrients in potency to stimulate GIP secretion, whereas there is a clear difference in time pattern, with peak levels seen at approximately 30–45 min after glucose and protein, whereas a prolonged action with peak levels after 2–3 h is seen after fat ingestion. Furthermore, also in model experiments in mice, we showed that glucose, protein and fat administration stimulate GIP secretion. In mice, glucose is more potent than protein and fat, with no significant difference between protein and fat. Finally, in mixed macronutrient ingestions, there is a synergy between the macronutrients on GIP secretion at moderate caloric doses, whereas at higher caloric doses by raising the glucose content, such synergy is lost and the effect is additive. We also suggest that further studies are warranted in humans to explore the relative potency of macronutrients, and whether synergistic effects might allow nutritional advice to optimize the secretion of this incretin hormone.

**ACKNOWLEDGMENTS**

This research was funded by the Lund University Medical Faculty. Tina Ovlund of Lund University is gratefully acknowledged for expert technical assistance. Open access funding enabled and organized by ProjektDEAL.
Ahrén

DISCLOSURE
The author declares no conflict of interest.
Approval of the research protocol: N/A.
Informed consent: N/A.
Registry and the registration no. of the study/trial: N/A.
Animal studies: Approved by the Lund/Malmö Animal Ethics Committee (Approval No. 5.8.18–06417/2020).

DEDICATION
This work is dedicated to Dr Susumo Seino, the great researcher and inspirer, who sadly passed away in 2021.

REFERENCES
1. Brown JC, Pederson RA, Jorpes E, et al. Preparation of highly active enterogastrone. Can J Physiol Pharmacol 1969; 47: 113–114.
2. Brown JC, Mutt V, Pedersen RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57–64.
3. Marks V. The early history of GIP 1969–2000: from enterogastrone to major metabolic hormone. Peptides 2020; 122: 170155.
4. Dupré J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826–828.
5. Turner DS, Etheridge L, Marks V, et al. Effectiveness of the intestinal polypeptide, IRP, GIP, VIP and motilin on insulin release in the rat. Diabetologia 1974; 10: 459–463.
6. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976; 99: 780–785.
7. Buffa R, Polak JM, Pease AG, et al. Identification of the intestinal cell storing gastric inhibitory peptide. Histochemistry 1975; 43: 249–255.
8. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159–166.
9. Örskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665–670.
10. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117–124.
11. Lindgren O, Mari A, Deacon CF, et al. Differential islet and incretin hormone responses in morning vs. afternoon after standardized meal in healthy men. J Clin Endocrinol Metab 2009; 94: 2887–2892.
12. Carr RD, Larsen MO, Jelic K, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, non-diabetic men. J Clin Endocrinol Metab 2010; 95: 872–878.
13. Alsalim W, Omar B, Pacini G, et al. Incretin and islet hormone adaptation to meals of increasing size in healthy subjects. J Clin Endocrinol Metab 2015; 100: 561–568.
14. Alsalim W, Ahrén B. Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects. Endocrinol Diabet Metab 2019; 2: e00056.
15. Nauck M, Schmidt WE, Ebert R, et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine and cholecystokinin-8. J Clin Endocrinol Metab 1989; 69: 654–662.
16. Gasbjerg LS, Helsted MM, Hartmann B, et al. Separate and combined glucometabolic effect of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes 2017; 68: 906–917.
17. Herrmann C, Göke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117–126.
18. Carr RD, Larsen MO, Sörhede Winzell M, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008; 295: E779–E784.
19. Alsalim W, Tura A, Pacini G, et al. Mixed meal ingestion diminished glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Diabet Obes Metab 2016; 18: 24–33.
20. Carper D, Coue M, Laurens C, et al. Reappraisal of the optimal fasting time for insulin tolerance tests in mice. Mol Metab 2020; 42: 101058.
21. Ovlund T, Pacini G, Ahrén B. Impact of incretin hormone receptors on insulin-independent glucose disposal in model experiments in mice. Front Endocrinol 2021; 12: 680153.
22. Nilsson M, Holst JJ, Björck IME. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose equivalent drinks. Am J Clin Nutr 2007; 85: 996–1004.
23. Ross SA, Brown JC, Dupré J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977; 26: 525–529.
24. Cataland S, Corckett SE, Brown JC, et al. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 1974; 39: 223–228.
25. Johansson Å, Olsson T, Cederquist K, et al. Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. Eur J Endocrinol 2002; 146: 397–405.
26. Cleator IGM, Gourlay RH. Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. Am J Surgery 1975; 130: 128–135.
27. Crockett SE, Mazzaferri EL, Cataland SE. Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus. *Diabetes* 1976; 25: 931–935.

28. Alsema M, Rijkwlijkhuizen JM, Holst JJ, et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. *Eur J Endocrinol* 2013; 169: 421–430.

29. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. *J Clin Endocrinol Metab* 2011; 96: 2519–2524.

30. Falk JM, Crockett SE, Cataland S, et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. *J Clin Endocrinol Metab* 1975; 41: 260–265.

31. Morgan LM, Tredger JAT, Hampton SM, et al. The effect of dietary modification and hyperglycaemia on gastric emptying and gastric inhibitory polypeptide (GIP) secretion. *Br J Nutr* 1988; 60: 29–37.

32. Ahlkvist L, Vikman J, Pacini G, et al. Synergism by individual macronutrients explains the marked early incretin and islet hormone responses to mixed meal challenge in mice. *Regul Pept* 2012; 178: 29–35.

33. Vilsboll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotrophic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. *Regul Pept* 2003; 114: 115–121.

34. Houghton LA, Mangnall YF, Read NW. Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers. *Gut* 1990; 31: 1226–1229.

35. Mesti L, Mengozzi A, Trico D. Impact of nutrient type and sequence on glucose tolerance: physiological insights and therapeutic implications. *Front Endocrinol* 2019; 10: 144.

36. Trommelen J, Weijzen MEG, van Kranenburg J, et al. Casein protein processing strongly modulates post-prandial plasma amino acid responses in vivo in humans. *Nutrients* 2020; 12: 2299.

37. Yamane S, Harada N, Inagaki N. Mechanisms of fat-induced gastric inhibitory polypeptide/glucose-dependent insulino tropic polypeptide secretion from K cells. *J Diabetes Investig* 2016; 7: 20–26.

38. Seino Y, Maekawa R, Ogata H, et al. Carbohydrate-induced secretion of glucose-dependent insulino tropic polypeptide and glucagon-like peptide-1. *J Diabetes Investig* 2016; 7: 27–32.

39. Poli E, Pozzoli C. Assessment of gastrointestinal propulsive activity using three different models of peristalsis in vivo in the mouse. *Curr Prot Toxicol* 2010; 46: 21–29.